With respect to CPGs, our findings strongly implicate BRCA2 pathogenic GVs in the tumorigenesis of adult gliomas (in line with [32, 51]), confirm that GVs in ATM, BRIP1, CDKN2A, MUTYH, PMS2, POLE, SDHA, TP53, and other CPGs are associated with glioma risk [15, 32, 51], and newly propose GVs in EGFR, GBA1, GJB2, and other CPGs as glioma predisposition candidates (Supplementary Tables 4, 5 online resource). This evidence concerns the gene TP53 and glioma.